AnalystsWilliam MaughanWilliam Maughan's Stock Forecasts
AnalystsWilliam Maughan
Sectors:
Analyst Ranking
Bottom 22%
#3277 out of 4174 analysts
Average Return
-4.44%
Win Rate
43%3 out of 7
Risk vs Reward
Poor
Good
William Maughan's 5 best and worst ratings
William Maughan Analyst Color
Get additional color on William Maughan's coverage of popular stocks
William Maughan's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Neoleukin Therapeutics IncNLTX | 2 | Hold | $1.00 | +69.49% | Downgrades | 3 months ago |
Y Mabs Therapeutics IncYMAB | 1 | Strong Buy | $27.00 | +476.92% | Maintains | 3 months ago |
Olema Pharmaceuticals IncOLMA | 1 | Strong Buy | $16.00 | +251.65% | Assumes | 7 months ago |
Xencor IncXNCR | 1 | Strong Buy | $50.00 | +37.02% | Assumes | 7 months ago |
Harpoon Therapeutics IncHARP | 1 | Strong Buy | $16.00 | +1,468.63% | Assumes | 7 months ago |
Biontech SeBNTX | 1 | Strong Buy | $192.00 | +35.15% | Assumes | 7 months ago |
Bicycle Therapeutics PLCBCYC | 1 | Strong Buy | $60.00 | +118.66% | Assumes | 7 months ago |
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTubeWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.